Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash & Equivalents (2020 - 2026)

Immuneering's Cash & Equivalents history spans 7 years, with the latest figure at $47.3 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 31.94% to $47.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $47.3 million, a 31.94% increase, with the full-year FY2025 number at $128.6 million, up 255.92% from a year prior.
  • Cash & Equivalents came in at $47.3 million for Q1 2026, down from $128.6 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $227.6 million in Q3 2025, with the low at $26.4 million in Q2 2025.
  • Historically, Cash & Equivalents has averaged $76.1 million across 5 years, with a median of $68.0 million in 2023.
  • Peak annual rise in Cash & Equivalents hit 403.4% in 2025, while the deepest fall reached 55.87% in 2025.
  • Year by year, Cash & Equivalents stood at $72.6 million in 2022, then dropped by 18.22% to $59.4 million in 2023, then plummeted by 39.16% to $36.1 million in 2024, then soared by 255.92% to $128.6 million in 2025, then plummeted by 63.22% to $47.3 million in 2026.
  • Business Quant data shows Cash & Equivalents for IMRX at $47.3 million in Q1 2026, $128.6 million in Q4 2025, and $227.6 million in Q3 2025.